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Purpose: To find the gene(s) responsible for macular telangiectasia type 2 (MacTel) by a candidate-gene screening
approach.
Methods: Candidate genes were selected based on the following criteria: those known to cause or be associated with
diseases with phenotypes similar to MacTel, genes with known function in the retinal vasculature or macular pigment
transport, genes that emerged from expression microarray data from mouse models designed to mimic MacTel phenotype
characteristics, and genes expressed in the retina that are also related to diabetes or hypertension, which have increased
prevalence in MacTel patients. Probands from eight families with at least two affected individuals were screened by direct
sequencing of 27 candidate genes. Identified nonsynonymous variants were analyzed to determine whether they co-
segregate with the disease in families. Allele frequencies were determined by TaqMan analysis of the large MacTel and
control cohorts.
Results: We identified 23 nonsynonymous variants in 27 candidate genes in at least one proband. Of these, eight were
known single nucleotide polymorphisms (SNPs) with allele frequencies of >0.05; these variants were excluded from
further  analyses.  Three  previously  unidentified  missense  variants,  three  missense  variants  with  reported  disease
association, and five rare variants were analyzed for segregation and/or allele frequencies. No variant fulfilled the criteria
of being causal for MacTel. A missense mutation, p.Pro33Ser in frizzled homolog (Drosophila) 4 (FZD4), previously
suggested as a disease-causing variant in familial exudative vitreoretinopathy, was determined to be a rare benign
polymorphism.
Conclusions: We have ruled out the exons and flanking intronic regions in 27 candidate genes as harboring causal
mutations for MacTel.
Macular telangiectasia type 2 (MacTel) is a rare, adult
onset retinal disease that results in tortuous and dilated retinal
vessels, macular pigment changes, macular edema, and in
some cases macular holes. It is also referred to in the literature
as idiopathic juxtafoveal, or juxtafoveolar, telangiectasia. A
classification system was introduced by Gass and Blodi [1]
and  updated  in  2006  by  Yannuzzi  [2],  distinguishing  the
features of three types of macular telangiectasias. MacTel, or
type 2, is a bilateral disease that affects both genders, as
opposed to type 1, which is often unilateral, with aneurism
and exudates, and generally presents only in men. Type 3,
characterized by occlusive telangiectasia, is very rare. The
three forms of idiopathic macular telangiectasia are described
together to distinguish and classify phenotypically similar
pathologies; however, the findings and progression of the
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three are distinct, and it is believed that each arises from a
distinct etiology.
In  2005,  The  MacTel  Project—an  international
consortium of clinicians and basic science researchers—was
established to study the cause, natural history, progression,
and epidemiology of the disease, and to explore potential
treatments. Publications from collaborators in the MacTel
Project have further described the clinical findings, diagnostic
methods, and epidemiology related to the disease [3-11]. In
advanced cases, neovascularization may be present, arising
from the intraretinal vascular plexus. While most reported
cases are sporadic, affected sib pairs and affected pairs of
monozygotic twins were described in the literature [12,13],
leading to the hypothesis that MacTel had a genetic cause in
a significant proportion of cases. Ophthalmic examination of
relatives of MacTel patients revealed that many families had
family  members  who  experienced  no  vision  loss,  but  did
exhibit  subtle  signs  of  the  disease  [14].  Since  vertical
transmission is observed in several families, an autosomal
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2718dominant  model  of  Mendelian  inheritance  with  reduced
penetrance is assumed.
In  conjunction  with  the  MacTel  Project,  we  have
assembled a cohort of MacTel patients and their relatives for
a genetic study. One mode of investigation in our studies has
been to identify the disease-causing gene(s) by the direct
sequencing of candidate genes in family probands, followed
by segregation analysis of families. The current hypothesis is
that a dominant causal mutation would be a rare heterozygous
variant in all affected individuals. Allele frequencies were
determined  by  screening  cases  and  controls  for  unknown
variants, and for known variants where population frequency
data was unavailable.
We  selected  candidate  genes  that  were  known  to  be
causative in diseases with phenotypic similarity to MacTel
(e.g., familial exudative vitreoretinopathy [FEVR] and Norrie
disease [15-19]), genes with a known molecular genetic role
in retinal vascularization or macular pigment transport, and
genes of functional interest that lay in regions of interest based
on  familial  linkage  studies.  Twenty-seven  genes  were
identified and screened based on these criteria.
METHODS
Study population: Participants were enrolled at 23 centers in
seven countries (Australia, Germany, France, the UK, Israel,
Switzerland, and the United States). Each center received
approval from their governing human subjects review board.
Informed  consent  was  obtained  in  accordance  with  the
Declaration of Helsinki. Records of informed consent and
human subject approvals for all participating centers were
centrally  managed  by  the  EMMES  Corporation.  Study
subjects were enrolled based on a diagnosis of MacTel by the
principal  investigator  at  each  center.  Further  criteria  for
enrollment were that patients be at least 18 years of age, be of
European ancestry, and be free of diabetic retinopathy or other
retinal  disease  [20].  Relatives  of  patients  diagnosed  with
MacTel were actively recruited. Age- and ethnicity-matched
controls were concurrently recruited—often a spouse or other
unrelated individual present at the clinic appointment with the
proband. At the time screening was performed, the MacTel
cohort  consisted  of  DNA  from  200  unrelated  probands
diagnosed with MacTel. Since March 2010, study enrollment
has been ongoing; a total of 735 samples have been sent to
Columbia University’s Center for Human Genetics. Of those
samples, 360 are unrelated cases, and the rest are mostly
unaffected relatives. The youngest MacTel proband in the
study was 25 years old at the time of enrollment, and the oldest
was 85. The majority of probands were between 50 and 70
years of age when they were enrolled.
The families of the probands sequenced consisted of five
affected sibling pairs (ASPs), two affected sibling trios, one
affected  parent  and  child  duo,  and  additional  relatives.
Specifically, family 8 (Figure 1) consisted of 11 individuals,
including an ASP, two additional unaffected siblings, one
affected and one unaffected parent, two uncles, and three
cousins. Family 9 consisted of an ASP and three unaffected
and one possibly affected offspring of the siblings. Families
22, 30, and 81 were ASPs. Family 29 was an affected sibling
trio plus six unaffected adult offspring of the siblings. Family
42 was a three-generation family consisting of an affected trio,
an affected uncle, three unaffected individuals in the second
generation, and three unaffected adult offspring in the third
generation. Family 101 was a discordant sibling pair with one
affected and one unaffected parent.
The  Columbia  University  control  cohort  consisted  of
DNA  samples  from  individuals  recruited  as  controls  for
studies  of  age-related  macular  degeneration  (AMD).
Participants were matched by age and ethnicity to the AMD
cohort, and were found free of macular disease at the time of
recruitment, as previously described [21,22]. Briefly, controls
underwent  ophthalmic  examination  to  screen  for  retinal
disease.  Stereo  fundus  photographs  were  evaluated  using
standard  classification  systems.  Individuals  accepted  as
controls had no family history of AMD, and were determined
to be free of retinal disease. Three hundred and sixty-eight
controls from the Columbia cohort were screened for this
study. In addition, a cohort of 639 AMD patients was screened
for selected variants. Data obtained from screening the AMD
cohort was beneficial in that the patients in this cohort were
of  advanced  age  and  had  undergone  thorough  retinal
examination, thereby ruling out MacTel and increasing the
number of individuals classified as controls.
Diagnosis of MacTel: Participants were given a standardized
ophthalmic  examination,  including  best  corrected  visual
acuity,  fundus  examination  with  photography,  fluorescein
angiography, optical coherence tomography, and blue light
reflectance. Images were taken and sent to Moorfields Eye
Hospital’s  Reading  Centre,  in  London,  England,  for
evaluation.  The  criteria  for  diagnosis  are  described  by
Clemons et al. [20]. Diagnostic features of MacTel are based
on  the  Gass  and  Blodi  criteria  [1],  and  include  loss  of
transparency  in  the  perifoveal  region,  dilated  and
telangiectatic blood vessels, especially in the temporal retina,
and crystalline deposits. In cases where the adjudication made
at the reading center was not in accordance with the diagnosis
made at the recruiting center, the reading center diagnosis was
used to code the sample for genetic studies. Each sample was
assigned  to  one  of  four  diagnostic  categories:  affected,
possibly  affected,  probably  not  affected,  or  unaffected.
Patients were reevaluated at regular intervals over the course
of the study.
Sequencing and genotyping: DNA was isolated from whole
blood  by  column  purification  (DNA  Blood  Maxi,  51194;
Qiagen, Valencia, CA). Eight probands of families with more
than one affected individual were screened by direct Sanger
sequencing for mutations in 27 candidate genes. For each
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2719gene,  primers  were  designed  to  amplify  each  exon  and
flanking intronic sequences. Primer sequences are listed in
Appendix 1. PCR reactions were performed with 2 ng of
genomic DNA in a total volume of 25 μg, using 25 pmol each
of forward and reverse primer, 200 μM dATP, dCTP, dGTP,
dTTP, 2.5 mM MgCl2, 1.5 U Taq Polymerase (Hot Fire DNA
Polymerase,  Solis  Biodyne,  Tartu,  Estonia,  or  AmpliTaq
Gold, Applied Biosystems, Carlsbad, CA), and 10× buffer
supplied by the manufacturer. Thermocycling was performed
using either the Stepdown protocol, or the Touchdown (68–
55 °C) protocol. Stepdown: an initial 12 min denaturation step
at 95 °C was followed by 12 cycles of 95 °C for 12 s, 65 °C
for 20 s (with a 0.5 °C reduction in temperature for each cycle),
and 72 °C for 55 s. This was followed by 30 cycles of 95 °C
for 12 s, 50 °C for 20 s, and 72 °C for 55 s, with a final 7 min
extension at 72 °C. Touchdown (68–55 °C): an initial 12 min
denaturation step at 95 °C was followed by 26 cycles of 95 °C
for 15 s, 68 °C for 20 s (with a 0.5 °C reduction in temperature
for each cycle), and 72 °C for 45 s. This was followed by 15
cycles of 95 °C for 15 s, 55 °C for 20 s, and 72 °C for 45 s,
with  a  final  7  min  extension  at  72  °C.  Sequencing  was
performed by Genewiz (South Plainfield, NJ). One hundred
and twelve familial samples were genotyped on the Illumina
(Illumina, Inc., San Diego, CA) 1M chip for ongoing linkage
studies (data not shown). These data were used to evaluate the
segregation  of  variants  detected  by  sequencing  when  the
variant was a known single nucleotide polymorphism (SNP)
that was genotyped on the chip.
Sequences were analyzed for known or unknown variants
that differed from the reference sequence. Nonsynonymous
coding  variants  were  evaluated  using  the  population
frequencies published in the Single Nucleotide Polymorphism
database  (dbSNP).  Unknown,  infrequent,  or  disease-
associated variants were evaluated to determine whether they
co-segregated with the disease within the families in which
they were discovered.
For known variants that were present in the Illumina 1M
chipset, genotypes of relatives in the family were inspected to
determine whether the variant co-segregated with the disease.
For unknown variants, and for rare variants not included on
the  1M  chip,  tests  for  co-segregation  were  performed  by
sequencing the family members of the proband in whom the
variant was detected. For variants detected in a family with
vertical  transmission,  where  both  parents  were  available,
segregation was assessed based on whether the allele was
inherited  from  the  affected  or  the  unaffected  parent.  For
variants detected in affected sib pairs whose parents were not
available, if the variant was present in both siblings, follow-
up  analysis  was  performed  by  TaqMan  assay  (Applied
Biosystems,  Foster  City,  CA)  in  the  cohort  of  MacTel
probands and in controls, to determine allele frequencies in
these cohorts. Variants that were determined to be common
polymorphisms based on population frequencies from dbSNP
were  not  pursued  further.  In  some  cases,  population
frequencies were not available in dbSNP, yet the variant was
highly polymorphic in the genotyped cohort and was present
in both affected and unaffected individuals. Such variants
were classified as frequent variants and not pursued further.
Variants  that  merited  further  analysis  either  because  co-
segregation of the variant with the disease could not be ruled
out,  or  because  the  allele  detected  was  rare  or  had  been
associated with disease, were screened by TaqMan assay in
Figure 1. Segregation of the p.Pro33Ser
(top)/p.Pro168Ser (bottom) compound
variant  in  a  family  with  inherited
macular  telangiectasia  type  2.  Black
filled circles represent affected family
members; blue filled circles represent
possibly affected family members. The
numbered  individuals  are  those  for
whom DNA was available for analysis.
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2720the entire MacTel cohort, and in a cohort of controls. For
selected variants, we also screened an available cohort of
AMD patients to determine allele frequencies more precisely.
Analyzing the large AMD cohort, in addition to the MacTel
and control cohorts, provided additional allele frequency data
for previously unknown variants and known variants where
population  frequency  data  was  unavailable.  Allele  and
genotype  frequencies  were  compared  between  cases  and
controls  with  standard  statistical  tests,  such  as  a  2x2
contingency table and Fisher’s exact text.
RESULTS
A summary of the screened genes grouped by selection criteria
is shown in Table 1. Descriptions of the genes screened and
the rationale for selecting candidate genes were as follows.
Genes  involved  in  angiogenesis:  One  of  the  defining
phenotypes of MacTel is the presence of telangiectatic blood
vessels in the retina and, in advanced disease, intraretinal
neovascularization.  This  form  of  neovascularization  is
prevalent  in  diabetic  retinopathy  and  in  retinopathy  of
prematurity  (ROP),  and  represents  about  10%–15%  of
neovascular changes in AMD [23-27]; the remaining 85%–
90% of neovascularization in AMD involves aberrant vessels
arising  from  the  choroidal  vasculature  (CNV).  The
vasculature  of  the  retina  is  highly  specialized;  thus,  the
specific location of the aberration is likely a result of highly
tissue-specific molecular genetic interactions. We selected 11
genes related to angiogenesis (Table 1), including the Wnt
receptor  frizzled-4,  its  ligand,  norrin  (NDP),  and  the  co-
receptor, low-density lipoprotein receptor-related protein 5
(LRP5). Mutations in these genes have been implicated in
FEVR, Norrie disease, and ROP [28-30]. Mouse knockout
models of frizzled homolog 4 (Drosophila); (FZD4) [15] and
NDP [31] show a lack of intraretinal vessel formation. Other
genes involved in angiogenesis or vessel regulation that were
screened are angiogenic factor with G patch and FHA domains
1  (AGGF1)  [32],  angiopoietin  1  (ANG1)  [33],  dickkopf
homolog 1 (Xenopus laevis); (DKK1) [34], hypoxia inducible
factor 1, alpha subunit (basic helix–loop–helix transcription
factor);  (HIF1A)  [35],  serpin  peptidase  inhibitor,  clade  F
(alpha-2  antiplasmin,  pigment  epithelium  derived  factor),
member 1 (PEDF) [36], thrombospondin 1 (THBS1) [37],
tyrosine  kinase,  endothelial  (TIE2)  [38],  and  von  Hippel-
Lindau tumor suppressor (VHL) [39].
Genes involved in macular pigment transport: MacTel is
also  characterized  by  macular  pigmentary  changes,  with
advanced cases often lacking macular pigment altogether.
Little  is  known  about  the  molecular  genetics  of  macular
pigment transport in the retina. In the healthy retina, the two
macular pigments, lutein and zeaxanthin, filter damaging blue
light [40,41]. The proteins responsible for lutein transport are
unknown.  The  macular  pigment  genes  screened  were
glutathione S-transferase pi 1 (GSTP1), a binding protein for
zeaxanthin [42], and scavenger receptor class B, member 1
(SCARB1), which has been proposed as a lipid transporter in
the retina [43].
Genes identified from expression arrays: Several genes
were screened that were identified as differentially expressed
in  mouse  models  intended  to  mimic  some  aspects  of  the
MacTel phenotype (data not shown). From the top of this list,
five genes were screened that were identified as also having
possible functional relevance by playing a role in MacTel:
apelin receptor (AGTRL1), apelin (APLN) [44], complement
factor  B  (CFB)  [45],  leucine-rich  alpha-2-glycoprotein  1
(LRG1),  and  plasmalemma  vesicle  associated  protein
(PLVAP) [46].
Genes  identified  from  suggestive  linkage  regions:
Linkage studies were performed using families in which at
least  one  family  member  in  addition  to  the  proband  was
diagnosed as affected by MacTel. While these results will be
reported  separately,  several  genes  of  possible  functional
interest were identified in regions of suggestive linkage on
chromosomes 1, 7, 10, and 12 during the course of analysis.
Cerebral cavernous malformation 2 (CCM2) [47], insulin-like
growth factor binding protein 3 (IGFBP3) [48], sarcospan
(Kras  oncogene-associated  gene);  (SSPN)  [49],  and
transforming  growth  factor,  beta  2  (TGFB2)  [50]  were
selected and screened as candidates under these criteria. Each
of  these  genes  has  been  proposed  to  be  involved  in
angiogenesis  or  regulation  of  blood  vessels;  IGFBP3  and
TGFB2 have also been proposed as genes related to diabetes.
Linkage  studies  are  ongoing  as  additional  families  are
recruited.
Genes involved in diseases with related phenotypes: An
increased prevalence of hypertension and diabetes are found
in MacTel patients [51]. Genes involved in these diseases,
which  are  also  expressed  in  the  retina,  especially  in  the
vasculature,  were  considered  as  candidates.  Succinate
receptor 1 (SUCNR1) [52], angiotensin II receptor, type 1
(AGTR1) [53], aldehyde dehydrogenase 3 family, member A2
(ALDH3A2) [54,55], very low density lipoprotein receptor
(VLDLR)  [56],  and  oxoglutarate  (alpha-ketoglutarate)
receptor  1  (OXGR1)  were  screened  on  this  basis,  in
conjunction with linkage or expression array data, or personal
communication with collaborators.
Table 1 summarizes the variants detected by the complete
sequencing of all exons and adjacent intronic sequences in 27
candidate  genes  in  eight  MacTel  probands.  In  total,  we
discovered three unknown and 20 known missense changes,
and  22  synonymous  and  61  intronic  variants.  Frequent
variants with reported minor allele frequencies (MAFs) over
0.10 were not analyzed further unless the variant was reported
to  be  disease-associated  (PEDF  p.Thr72Met  and  GSTP1
p.Ile105Val were screened in cases and controls, though they
are frequent variants). Variants with published population
frequencies  between  5%–10%  were  assessed  for  further
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2721TABLE 1. GENES SEQUENCED AND MISSENSE VARIANTS DETECTED BY SANGER SEQUENCING IN 8 MACULAR TELANGIECTASIA PROBANDS.
Gene/
category
Variant rs number MAF MacTel cases (400
chromosomes) /MAF AMD cases
(1278 chromosomes)
MAF Controls (736
chromosomes)
MAF
dbSNP
Notes
Vascular/angiogenic
AGGF1 p.Pro698Thr rs34400049 NS NS 0.28 FV, DNS
ANG1 p.Thr257Arg - 0.005 (1/400) 0 (0/736) - DNS
DKK1 None          
FZD4 p.Pro33Ser rs61735304 0.02 (6/400)/.03 (17/1278) 0.01 (13/736) ND DNS, MT,
AMD
  p.Pro168Ser - NS NS - Allelic
with P33S
HIF1A None          
LRP5 p.Val667Met rs4988321 0.07 (28/400) 0.06 (41/736) 0.03 MT, DNS
p.Gln1192Arg - 0.005 (1/400) 0 (0/736) - MT, DNS
p.Ala1130Val rs3736228 NS NS 0.12 FV, DNS
NDP None          
PEDF p.Thr72Met rs1136287 0.37 (148/400)/.34 433/1278) 0.33 (245/736) 0.36 FV, MT,
AMD
THBS1 p.Thr523Ala rs2292305 NS NS 0.1 FV, DNS
TIE2 p.Val486Ile rs1334811 NS NS 0.03 DNS
  p.Val600Leu rs35030851 NS NS 0.04 DNS
VHL None          
Expression microarray
AGTRL1 None          
APLN None          
CFB p.Leu9His rs4151667 0.04 (16/400)/.02 (23/1278) 0.04 (29/736) 0.07 DNS, MT,
AMD
  p.Arg32Gln rs641153 0.10 (40/400)/.04 (51/1278) 0.12 (88/736) 0.1 DNS, MT,
AMD
  p.Gly252Ser rs4151651 NS NS 0.04 DNS
  p.Lys533Arg - 0.04/.02 (23/1278) 0.04 (29/736) - DNS,
AMD, LD
LRG1 p.Pro133Ser rs966384 NS NS 0.35 DNS, FV
PLVAP            
Macular pigment
GSTP1 p.Ile105Val rs1695 0.33 (132/400)/.30 (383/1278) 0.3 0.39 MT,
AMD, FV
  p.Ala114Val rs1138272 0.08 (32/400)/.07 (87/1278) 0.06 (46/736) 0.12 MT,
AMD, FV
SCARB1 p.Val135Ile rs5891 0.03 (12/400) 0.02 (15/736) 0.01 MT DNS
  p.Pro376Leu rs74830677 0.01 (3/400) 0.01 (5/736) 0.05 MT, DNS
Genes under suggestive linkage peaks
CCM2 p.Val120Ile rs11552377 NS NS 0.17 FV, DNS
IGFBP3 None          
SSPN None          
TGFB2 None          
Disease related genes
AGTR1 p.Ala244Ser rs12721225 NS NS 0.03 DNS
ALDH3A2 None          
OXGR1 p.Thr205Ala - 0.005 (1/400) 0 (0/736) - DNS
SUCNR1 None          
VLDLR None          
NS represents not screened, ND represents not determined, FV represents frequent variant, DNS represents Does not segregate
with disease,  MT represents Screened in MacTel cases and controls, AMD represents Screened in AMD cohort. LD represents
the CFB  p.Lys533Arg variant is in complete linkage disequilibrium with p.Leu9His. No comparison between MacTel cases and
controls reached statistical significance.
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2722screening, based on whether the variant had been reported to
be associated with any diseases with phenotypes similar to
that of MacTel. Twelve missense variants were screened by
TaqMan  assay  (Table  1)  in  MacTel  cases  and  unaffected
controls; six of these variants were also screened in a large
AMD cohort. Of the variants detected, three were unknown
(ANG1  p.Thr257Arg,  LRP5  p.Gln1192Arg,  and  SCARB1
p.Ile135Val), three had been reported as possibly disease-
associated  (FZD4  p.Pro33Ser,  GSTP1  p.Val105Ile,  and
PEDF p.Thr73Met). The remainder had low reported MAFs.
None of the variants found by sequencing segregated with the
disease.  Of  the  variants  screened  by  TaqMan  assay,  only
GSTP1  p.Val105Ile  showed  a  trend  toward  a  statistically
significant frequency difference between cases and controls
(p=0.09), suggesting it could be a possible modifier, but not a
causal gene for MacTel.
The FZD4 variants p.Pro33Ser and p.Pro168Ser were
detected  in  the  proband  III2  (family  8,  Figure  1).  We
sequenced  all  members  of  family  8  and  found  both  the
p.Pro33Ser and p.Pro168Ser variants present in two affected
daughters,  one  unaffected  daughter,  and  one  unaffected
cousin  of  the  proband,  indicating  that  the  complex  allele
containing both mutations did not segregate with the disease
(Figure 1). The p.Pro33Ser variant was analyzed by TaqMan
assay in 200 MacTel cases, 368 unrelated controls, and 639
AMD cases to determine allele frequencies. This variant was
found  in  one  other  unrelated  MacTel  proband  (A5).  The
p.Pro168Ser mutation was also present in each individual
carrying p.Pro33Ser. Thirteen controls were heterozygous for
p.Pro33Ser (MAF=0.018). In 639 unrelated AMD samples,
16 heterozygotes and one homozygote for p.Pro33Ser were
detected  (MAF=0.013).  In  conclusion,  there  was  no
statistically  significant  difference  in  allele  frequencies
between cases and controls.
DISCUSSION
We  have  shown  that  the  FZD4  p.Pro33Ser  /p.Pro168Ser
complex allele, which has been reported as causative in FEVR
and ROP [57,58], is present in 2% of unaffected controls, and
therefore is not a disease-causing variant in MacTel, FEVR,
or ROP. The same allele was detected in one MacTel patient,
prompting the hypothesis that FEVR and MacTel may be
allelic diseases. Given that FEVR has phenotypic similarities
to MacTel, in that the intraretinal vascular plexus is perturbed
in  both  diseases,  dysregulation  of  FZD4  was  a  plausible
hypothesis in the etiology of MacTel. Both FEVR and MacTel
also  exhibit  variable  expressivity  [59].  In  both  diseases,
affected  family  members  are  often  unaware  that  they  are
affected until a diagnosis is made after thorough examination.
Segregation analysis in one MacTel family and case-control
association analysis using a large cohort of controls revealed
that p.Pro33Ser /p.Pro168Ser, which had been reported as a
disease causing mutation, rather, is a benign polymorphism
present  at  a  low  frequency  in  the  general  population.
Accordingly, we conclude that it is not causative in either
MacTel  or  FEVR,  because  our  control  cohort  had  no
documented  retinal  disease.  This  result  highlights  the
importance  of  segregation  analysis  in  families,  and  of
screening  a  sufficient  number  of  controls  to  distinguish
between causal mutations and rare benign polymorphisms.
Candidate gene screening is a widely used method for
detecting disease-associated variants and genes. While often
criticized as a “needle in a haystack” approach, it has been
successful  in  determining  some  disease-associated  genes,
most notably the major AMD-associated genes, CFH and
CFB [21,22]. In this study, 27 possible candidate genes for
MacTel were selected based on a combined set of criteria. The
exons and flanking intronic regions of all genes were screened
by direct sequencing, with follow-up segregation analysis in
families and TaqMan genotyping in large cohorts for rare,
unknown, or previously disease-associated missense variants.
No variants segregated with the disease, and none showed
significant association with MacTel, allowing exclusion of the
coding regions of these genes as harboring a causal mutation
for MacTel. The causal gene(s) for MacTel are currently being
searched for by a combination of linkage analyses and whole-
genome sequencing.
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Appendix 1. Primer sequences of candidate genes sequenced (5′ −3′).
To access the table, click or select the words “Appendix 1.”
This  will  initiate  the  download  of  a  pdf  archive  that
contains the table.
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